From the Departments of Surgery (Drs Johnson, Moore, Tamura, and Zallen and Mr Patrick) and Pediatrics (Mr Elzi and Dr Silliman), Denver Health Medical Center, University of Colorado Health Sciences Center; and the Bonfils Blood Center (Mr Elzi and Dr Silliman), Denver.
This article was corrected | View correction
Inflammatory stimuli rapidly activate mitogen-activated protein kinases (MAPKs) in neutrophils (PMNs). However, their role in cytotoxic function remains unknown. Elucidating the signals involved in release of cytotoxic agents from PMNs may provide new avenues for therapy in diseases of diminished or excessive PMN function.
The p38 MAPK and extracellular signal-related kinase 1/2 (ERK1/2) modulate superoxide generation and elastase release in activated human PMNs.
Isolated human PMNs were incubated with specific inhibitors of MAPK pathways, or vehicle control solution, before activation with the bacterial peptide f-Met-Leu-Phe.
Main Outcome Measures
The rate of superoxide release from activated PMNs was measured by the superoxide dismutase–inhibitable reduction of cytochrome-c. Elastase release from PMNs was determined by cleavage of the substrate Ala-Ala-Pro-Val-pNA.
Superoxide release from activated PMNs was inhibited by blockade of p38 MAPK activation but unaffected by blockade of ERK1/2. Conversely, elastase release was unaffected by p38 MAPK inhibition and increased by ERK1/2 inhibition.
Activation of p38 MAPK promotes superoxide release from PMNs activated by f-Met-Leu-Phe. The ERK1/2 pathway may serve as a negative feedback mechanism for granule exocytosis.
THE NEUTROPHIL (PMN) is a critical effector of the response to invading microorganisms, as evidenced by disorders of diminished PMN microbicidal function such as chronic granulomatous disease.1 On the other hand, excessive PMN activity has also been implicated in disease, including the hyperinflammatory states of adult respiratory distress syndrome and multiple-organ failure.2 Appropriate regulation of PMN cytotoxic mechanisms is thus crucial to the well-being of the host and may represent an emerging area for therapy in the critical care setting. Developing such strategies to modify inflammatory responsiveness, however, will hinge on our understanding of the cellular signaling that determines PMN cytotoxic function.
Mitogen-activated protein kinases (MAPKs) encompass a group of enzymes recruited in response to cellular stress, including heat stress, osmotic stress, cytokines, and UV irradiation.3 The accepted role of MAPKs is to produce cellular responses to those stresses by integrating multiple stimuli and activating transcription factors. In most cell lines, MAPKs have been implicated in regulating mitogenic responses and the synthesis of stress response proteins.4 To date, the following 3 major MAPK families have been characterized: p38 MAPK, extracellular signal-related kinase 1/2 (ERK1/2 or p42/44 MAPK), and stress-activated protein kinase (SAPK/JNK). Although they are often thought of and presented as parallel pathways, there is evidence of crosstalk between these families, and the net result of their activation is likely to be an integration of multiple effector mechanisms.
The PMN is a terminally differentiated cell with a limited cell cycle and synthetic repertoire. Nonetheless, recent work has demonstrated that 2 of the MAPK families (p38 MAPK and ERK1/2) are present in PMNs, and are activated within seconds by a variety of stimuli, including bacterial peptides, cytokines, lipopolysaccharides, and chemoattractants.5- 8 However, the potential mechanistic role of this MAPK activation with respect to PMN cytotoxic function remains to be elucidated.
MAPKs are activated by dual phosphorylation via an upstream MAP ERK (MEK). The 2 such pathways that have been described in the PMN are shown in Figure 1. The first, p38 MAPK (activated by MEKs 3, 4, and 6), was originally described in yeast as an effector of response to osmotic stress. In the PMN, its function is unknown, although some protein targets have been described,9 and its activation has been associated with an exaggerated or primed PMN response.10 The second MAPK pathway activated in stimulated PMNs is ERK1/2 (activated by MEKs 1 and 2), which, in other cell lines, is important in mitogenic responses. Because the PMN is not capable of proliferation, the significance of ERK1/2 activation in these cells, if any exists, remains a puzzle. The enzymes of the stress-activated protein kinase pathway are presumably present in PMNs. To our knowledge, however, stimulation of this cascade has not been associated with the initiation of PMN cytotoxic function.
Mitogen-activated protein kinase (MAPK) pathways in neutrophils associated with the activation of cytotoxic mechanisms. ERK1/2 indicates extracellular signal-related kinase 1/2; MEK, MAP-ERK.
Recognition of MAPK involvement in PMN cytotoxic function would represent a relatively novel role for MAPKs in rapid cellular responses. Furthermore, elucidation of these PMN-signaling pathways may provide new avenues for therapeutic manipulation of cytotoxic function in syndromes of excess PMN function (eg, multiple-organ failure) or syndromes of blunted PMN function (eg, postburn susceptibility to sepsis). We sought to characterize the role of the p38 MAPK and ERK1/2 pathways in the cytotoxic function of the PMN. Two key PMN responses responsible for microbicidal and cytotoxic activity are the release of superoxide anion (O2−) and the release of granule contents (eg, the proteolytic enzyme elastase).11 We interrogated the role of MAPK pathways in these responses by incubating PMNs with specific inhibitors of these pathways before activating the cells. The results of our study indicate that these 2 signaling cascades serve opposite roles in cytotoxicity: p38 MAPK activity promotes superoxide release, whereas ERK1/2 activity inhibits the release of granule contents.
Reagents were obtained from Sigma-Aldrich Corporation, St Louis, Mo, unless otherwise specified. All solutions for cell separation were prepared in a sterile fashion using endotoxin-free water and filtered through 0.22-µm filters. The p38 MAPK inhibitor SB 20358012 and MEK1/2 inhibitor PD 9805913 were obtained from Calbiochem, La Jolla, Calif. Inhibitors were dissolved in dimethyl sulfoxide and diluted 1:100 in cell suspensions to produce final concentrations of 0.1 to 100 µmol/L.
Blood drawn from healthy human volunteers was anticoagulated with 10 U/mL of heparin and mixed with an equal volume of 3% dextran in 0.9% isotonic sodium chloride solution. The whole blood-dextran admixture sedimented for 25 minutes, and the leukocyte-rich upper layer was removed and centrifuged for 10 minutes at 200g. The resultant pellet was resuspended in 8 mL of room-temperature, phosphate-buffered isotonic sodium chloride solution and layered over 5 mL of Ficoll (Pharmacia Biotech, Upsalla, Sweden). The layered solutions were centrifuged at 400g for 30 minutes. All subsequent isolation steps were performed at 4°C. Residual erythrocytes were removed by hypotonic lysis, and the remaining cells were resuspended in Kreb-Ringer phosphodextrose (pH 7.35) at a final concentration of 2.5 × 106 cells/mL. Neutrophils prepared in this matter were more than 98% pure on results of Wright stain and more than 98% viable on results of trypan blue exclusion.
Cells were warmed to 37°C for 5 minutes before any treatment. Cells were preincubated with the MEK1/2 inhibitor PD 98059 (10−4 to 10−6 mol/L), the p38 MAPK inhibitor SB 203580 (10−5 to 10−7 mol/L), or vehicle (dimethyl sulfoxide at a final concentration of 1%) for 30 minutes. Cells were then activated with the bacterial formyl peptide f-Met-Leu-Phe (fMLP, 1 µmol/L).
Aliquots of 1 million PMNs each were activated with fMLP (1 µmol/L) and assessed for activation of p38 MAPK and ERK1/2 using immunoblotting with antibodies specific to the active forms (dual phosphorylated) of these enzymes (New England Biolabs, Beverly, Mass). Briefly, activated cells were lysed at varying time points in sample buffer (Owl Scientific, Woburn, Calif) containing phenylmethylsulfonyl fluoride, leupeptin, sodium orthovanadate, and nitrophenylphosphate. Cell lysates were boiled for 5 minutes, and the proteins were separated on a polyacrylamide gel of 4% to 20% gradient under reducing conditions. Proteins were then transferred to a polyvinylidene difluoride membrane and detected using antibody labeling and chemiluminescence with a horseradish peroxidase–conjugated secondary antibody. In selected experiments, PMNs were preincubated with PD 98059, which selectively inhibits the phosphorylation of ERK1/2. Because SB 203580 does not block the phosphorylation of p38 MAPK (rather, it blocks enzymatic activity by binding the adenosine triphosphate site on the protein), this compound was not used in the immunoblot preparations.
Elastase release was measured after 10 minutes of activation by incubation of supernatants from PMNs with the substrate methoxysuccinyl-Ala-Ala-Pro-Val-pNA (AAPV-pNA). Cells were pelleted using centrifugation, and the supernatant was incubated for 1 hour at 37°C in a buffer of combined HEPES and sodium chloride (pH 7.5) containing AAPV-pNA (final concentration, 0.33 mmol/L). Cleavage of the substrate with release of the colored product pNA was measured using optical density at 405 nm in duplicate wells, minus control wells containing the elastase inhibitor methoxysuccinyl-AAPV-chloromethyl ketone. Data are expressed as a percentage of total cell elastase (cells lysed with 0.1% Triton X-100).
The rate of O2− release was measured by the superoxide dismutase–inhibitable reduction of ferricytochrome-c in 96-well microtiter plates. Cells were suspended at 2.5 × 106 cells/mL in a final volume of 150 µL of Kreb-Ringer phosphodextrose containing 75-µmol/L cytochrome-c. Duplicate-reaction wells were used and compared with a single control well containing 3 µg/mL superoxide dismutase. Immediately after the addition of fMLP, the plates were read at 550 − 450 nm every 20 seconds for 5 minutes. The maximal rate of production of O2− (Vmax) was calculated using 5 points on the curve (100-second interval). Results are expressed as nanomoles per minute per 3.75 × 105 cells.
All data are expressed as mean±SEM and underwent analysis of variance with Dunnett correction for planned multiple comparisons.
Activated forms of these enzymes were not detected in unstimulated PMNs. Figure 2 shows that, after stimulation with 1-µmol/L fMLP, both MAPKs rapidly phosphorylated, peaking at 60 to 90 seconds. Consistent with its reported activity, PD 98059 inhibited the activation of ERK1/2 in a dose-dependent fashion, with nearly complete inhibition at 10 µmol/L (Figure 3).
Activation of extracellular signal-related kinase 1/2 (left) and p38 mitogen-activated protein kinase (right) after stimulation with f-Met-Leu-Phe (1 µmol/L for 1 minute). Antibody to the dual-phosphorylated (active) forms of these enzymes detected protein after 1 minute; none was detected in control cells.
Inhibition of extracellular signal-related kinase 1/2 (ERK1/2) activation (f-Met-Leu-Phe [fMLP], 1 µmol/L for 1 minute) by the specific inhibitor PD 98059 (1 and 10 µmol/L). Substantial but not complete inhibition of ERK1/2 phosphorylation was achieved with 10-µmol/L PD 98059.
Incubation of PMNs with the p38 MAPK inhibitor SB 203580 produced a dose-dependent decrease in the rate of superoxide production in response to fMLP (Figure 4). Control cells (preincubated with dimethyl sulfoxide) produced superoxide at a Vmax of 0.35±0.05 nmol/min per 3.75 × 105 cells, whereas cells treated with 1 and 10 µmol/L SB 203580 produced 0.15±0.04 and 0.21±0.06 nmol/min per 3.75 × 105 cells, respectively. Although there was a trend toward less inhibition with the 10-µmol/L dose, this did not reach statistical significance. The MEK1/2 inhibitor PD 98059 had no effect on superoxide produced in response to fMLP when compared with vehicle control, even at concentrations well above the median effective concentration (EC50) for the compound (about 10 µmol/L) (data not shown).
Effect of p38 mitogen-activated protein kinase inhibition (using specific inhibitor SB 203580) on release of superoxide anion from f-Met-Leu-Phe–stimulated neutrophils. Asterisk indicates P<.05.
Although inhibition of p38 MAPK decreased oxidant production by fMLP-stimulated PMNs, there was no effect on release of granule contents (data not shown), even at doses well above the EC50 of the SB 203580 compound (about 1 µmol/L). In contrast, inhibition of MEK1/2 had an effect on degranulation, as measured by release of elastase. The PD 98059 produced a dose-dependent increase in release of elastase (Figure 5). Control cells released 11.39%±1.36% of their elastase after fMLP stimulation, which was increased to as much as 24.31%±3.21% with MEK1/2 inhibition.
Effect of mitogen-activated protein–extracellular signal-related kinase 1 and 2 inhibition (using inhibitor PD 98059) on release of elastase from f-Met-Leu-Phe–stimulated neutrophils. Asterisk indicates P<.05.
Our study supports the hypothesis that MAPK activation is important in the regulation of PMN cytotoxic function. Furthermore, it underscores the concept that parallel MAPK pathways are not functionally redundant but, rather, act to integrate responses to stimuli. In the PMN, our results suggest that, although p38 MAPK promotes cytotoxic function, simultaneous activation of the ERK1/2 pathway may serve as a negative feedback mechanism for granule release.
Previous investigators have characterized a role for the activation of MAPK pathways in response to stress using multiple cell types. In general, MAPK activation is thought to be integral to mitogenic responses and mediated primarily through transcription factors and the modification of protein synthesis. However, the rapid (within seconds) activation of 2 such MAPK pathways in the PMN, a terminally differentiated cell, suggested that MAPKs can serve other roles. The stimuli shown to activate the p38 MAPK and ERK1/2 pathways in the PMN are the same stimuli that provoke its cytotoxic function. For instance, p38 MAPK activation has been described in the PMN in response to bacterial products (eg, fMLP, lipopolysaccharide) and cytokines (tumor necrosis factor and granulocyte colony-stimulating factor).5- 7,14- 17 The fMLP results in the rapid activation of p38 MAPK and ERK1/2 in human PMNs.10 Our results show that activation of p38 MAPK is necessary for normal release of O2− in response to fMLP. Inhibition of p38 MAPK decreased the fMLP-stimulated production of superoxide by 57%±14%. In contrast to our findings with the p38 MAPK pathway, the ERK1/2 pathway did not appear to stimulate cytotoxic function, but rather attenuate it, as ERK1/2 inhibition increased elastase release in response to fMLP by as much as 113%±61%.
Other investigators have recently examined the role of MAPKs in oxidant production by PMNs. Our results agree with those of Zu et al,17 who used an end point assay for superoxide to show that total oxidant production in 3 minutes was reduced by 92% after treatment with SB 203580. The more pronounced effect they observed may be due to the fact that they preincubated with the inhibitor for 40 minutes before rewarming the cells, which may not be an ideal model for therapeutic application of p38 MAPK inhibitors. These authors, as well as Coffer et al,14 also found no effect of ERK1/2 inhibition on oxidant production.
The role of MAPK pathways in degranulation is less well defined. A single report16 suggested a role for ERK1/2; however, the study used neutrophils pretreated with cytochalasin B, which perturbs the cytoskeleton and makes results concerning mobilization of granules difficult to interpret. The apparent inhibitory role of ERK1/2 in PMN degranulation may prove to be via the induction of cellular phosphatase activity and, therefore, termination of the activity of enzymes activated by phosphorylation. Recently, ERK1/2 has been shown to induce phosphatases specific for MAPKs.18,19 Although p38 MAPK has now been implicated in several PMN cytotoxic functions, including oxidant production, chemotaxis, and cytokine production,14,16 it appears to have no role in the release of granule contents. This argues that specific elements of PMN cytotoxic mechanisms are regulated independently, and not in an all-or-none fashion. Indeed, we have noted disparate changes in oxidant production and elastase release in patients after injuries (J.L.J. and E.E.M., unpublished observations, October 1998). This has important implications for the potential therapeutic application of agents that alter PMN function.
As our understanding of the cellular control of PMN cytotoxic function develops, we may be able to develop novel strategies to modify the inflammatory response. The present finding that p38 MAPK serves a proinflammatory role in the PMN may provide a target for therapy in hyperinflammatory states. Indeed, our work in pulmonary endothelial cells20 corroborates a proinflammatory role for p38 MAPK in adhesion molecule expression and, thus, the potential for regulating PMN-endothelial interactions. Inhibition of p38 MAPK activity may provide an avenue for controlling the cytotoxic potential of primed PMNs, which have been implicated in the pathogenesis of adult respiratory distress syndrome and multiple-organ failure.21 The finding that ERK1/2 may serve a negative feedback role in granule release may have similar implications for the diagnosis and treatment of disease. For instance, because elastase release is a central mechanism of cell death after CD18–intercellular adhesion molecule-1 interactions,22 augmentation of ERK1/2 activity may prove to be a useful tool in preventing damage to the host during syndromes characterized by neutrophil sequestration. Of course, because MAPK pathways are found in many cells, the clinical efficacy of manipulating these signaling events remains to be proven.
The study was supported in part by grants P50GM49222 and T32GM08315, and Clinical Associate Physician Award M01-RR00069 (Dr Silliman) of the General Clinical Research Centers Program, National Institutes of Health, Bethesda, Md.
Presented at the 18th Annual Meeting of the Surgical Infection Society, New York, NY, May 1, 1998.
The neutrophil (PMN) has been implicated as a principal effector of organ injury in adult respiratory distress syndrome and multiple organ failure. In these hyperinflammatory states, PMNs are thought to release their cytotoxic products indiscriminately, resulting in tissue injury. Although perturbations of PMN responsiveness are well described, strategies for therapeutic intervention have been limited largely to leukodepletion and the global disarming of PMNs. In the clinical realm, it may be more appropriate to modulate PMN cytotoxicity more precisely, such as at the level of cellular signaling. This study describes signaling cascades that are potential targets in the pharmacological control of PMN responsiveness. Specifically, we describe how the family of mitogen-activated protein kinases (MAPKs) modify the release of reactive oxygen species and proteases from PMNs. Our findings indicate that the rapid activation of MAPKs following PMN stimulation has pivotal functional significance. Specifically, activation of the p38 MAPK augments superoxide anion release, whereas activation of the parallel extracellular signal-related kinase 1/2 pathway simultaneously inhibits elastase release. We surmise that discrete manipulation of these pathways may allow for therapeutic intervention in patients with perturbed PMN function.
Corresponding author: Ernest E. Moore, MD, Department of Surgery, Denver Health Medical Center, 777 Bannock St, Denver, CO 80204.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.